Core Insights - Voyager Therapeutics is advancing its clinical programs targeting tau-related neurological diseases, with VY7523 clinical data expected soon and VY1706 anticipated to enter clinical trials in 2026 [1][11] Financial Performance - For Q3 2025, Voyager reported collaboration revenue of $13.4 million, a decrease from $24.6 million in Q3 2024, primarily due to prior year revenue from the Novartis agreement [12] - Research and development expenses increased to $35.9 million in Q3 2025 from $30.2 million in Q3 2024, driven by costs associated with the VY7523 clinical trial and VY1706 program [12] - The net loss for Q3 2025 was $27.9 million, compared to $9.0 million in Q3 2024, attributed to reduced collaboration revenue [12] Pipeline Developments - The VY7523 anti-tau antibody is currently in the final cohort of a clinical trial for Alzheimer's disease [5] - VY1706, a tau silencing gene therapy, is undergoing IND-enabling studies with clinical trial initiation expected in 2026 [5][11] - Voyager introduced the Voyager NeuroShuttle, a nonviral delivery platform, which has shown promising results in preclinical studies for delivering neurotherapeutics across the blood-brain barrier [4][5] Collaborations and Partnerships - Voyager has entered a collaboration with Transition Bio to develop small molecules targeting TDP-43 for ALS and frontotemporal dementia, with potential milestone payments up to $500 million [6] - Neurocrine Biosciences is expected to provide updates on IND filing timelines for their gene therapy programs by the end of 2025, which could lead to clinical trials in 2026 [5] - Novartis has decided to discontinue two discovery-stage programs, returning rights to Voyager, but this will not affect Voyager's cash runway guidance [5] Cash Position and Financial Guidance - As of September 30, 2025, Voyager's cash position was $229 million, sufficient to maintain operations into 2028 [4][9] - The company anticipates potential non-dilutive capital of up to $2.4 billion from development milestone payments, including $35 million from GBA and FA programs entering the clinic [9]

Core Insights - Legend Biotech Corporation is presenting new data on CARVYKTI (ciltacabtagene autoleucel) for multiple myeloma at the 2025 ASCO and EHA meetings, highlighting its status as a market leader in CAR-T therapy for this condition [1][2] - The company is also showcasing preliminary results from ongoing Phase 1 studies targeting solid tumors, specifically lung and gastric cancers, indicating an expansion of its cell therapy pipeline [1][2] CARVYKTI Data - Long-term data from the CARTITUDE-1 study will be presented, showing that heavily pretreated patients with relapsed or refractory multiple myeloma achieved a median progression-free survival of over 5 years after a single CARVYKTI infusion, with a median follow-up of 60.3 months [3][10] - Data from the CARTITUDE-4 study will support a positive benefit-risk ratio for CARVYKTI across various patient subgroups, including those with high-risk cytogenetics [4][10] Solid Tumor Pipeline - Preliminary results from Phase 1 studies of LB2102 and LB1908, targeting small-cell lung cancer and gastroesophageal adenocarcinoma respectively, will be featured in poster presentations at ASCO [6][10] - LB2102 has been licensed to Novartis for further development, with Legend Biotech responsible for the Phase 1 clinical trial in the U.S. [7][8] Clinical Presentations - The company will present data at ASCO and EHA, including an oral presentation on long-term survival outcomes for CARVYKTI and poster presentations on subgroup analyses and preliminary results from solid tumor studies [10][12]

Core Insights - Voyager Therapeutics reported a strong cash position of $295 million, expected to last until mid-2027, excluding potential milestone payments from partnerships [2][8] - The company is advancing its pipeline, particularly focusing on tau-targeting programs for Alzheimer's disease, with IND submissions anticipated in 2026 [2][5] Financial Results - Collaboration revenue for Q1 2025 was $6.5 million, down from $19.5 million in Q1 2024, primarily due to decreased revenue from Neurocrine collaboration [14] - Net loss for Q1 2025 was $31.0 million, compared to $11.3 million in Q1 2024, attributed to lower collaboration revenue and increased operating expenses [14][19] - Research and development expenses increased to $31.5 million in Q1 2025 from $27.1 million in Q1 2024, driven by higher program-related spending [14][19] Pipeline and Development Updates - The tau silencing gene therapy VY1706 demonstrated up to 73% knockdown of tau mRNA in non-human primates after a single intravenous dose [5] - The company is preparing for IND submissions for VY1706 and the Neurocrine-partnered Friedreich's ataxia and GBA1 programs in 2026 [6][14] - Voyager's anti-tau antibody VY7523 is currently in a multiple ascending dose clinical trial for Alzheimer's Disease, with initial tau PET data expected in the second half of 2026 [6][14] Upcoming Milestones - Multiple presentations at the ASGCT 2025 annual meeting are planned, including data on VY1706 and VY7523 [5][6] - The initiation of clinical trials for the FA and GBA1 programs is expected in 2026, with potential milestone payments totaling $35 million [6][14]

Core Insights - UNITY Biotechnology, Inc. has appointed Dr. Yehia Hashad to its board of directors and science committee, enhancing its leadership in ophthalmology as it prepares for the Phase 2b ASPIRE trial data readout for UBX1325 [1][2] Company Overview - UNITY is focused on developing therapeutics aimed at slowing, halting, or reversing diseases associated with aging, particularly in ophthalmologic and neurologic fields [4] Leadership and Expertise - Dr. Hashad brings over 25 years of experience in clinical and commercial drug development, having previously held leadership roles at Bausch + Lomb and Allergan Aesthetics, overseeing numerous pharmaceutical programs [2][3] - His expertise in ophthalmology is expected to be crucial for advancing UBX1325, a treatment for diabetic macular edema [2][3] Strategic Goals - The company aims to leverage Dr. Hashad's insights to optimize its strategy for UBX1325 and to develop a robust pipeline of future products targeting retinal diseases [2][3]

Financial Performance - Total revenue for 4Q24 was $88.3 million, a 19% increase compared to $74.1 million in 4Q23[13, 23] - Software revenue for 4Q24 was $79.7 million, a 16% increase compared to $68.7 million in 4Q23[13, 23] - Drug discovery revenue for 4Q24 was $8.7 million, a 58% increase compared to $5.5 million in 4Q23[13, 23] - Total revenue for FY24 was $207.5 million, a 4.2% decrease compared to $216.7 million in FY23[13, 25] - Software revenue for FY24 was $180.4 million, a 13% increase compared to $159.1 million in FY23[13, 25] - Drug discovery revenue for FY24 was $27.1 million, a 53% decrease compared to $57.5 million in FY23[13, 25] 2025 Financial Guidance - The company expects software revenue growth of 10% - 15% in 2025[13, 43] - The company expects drug discovery revenue between $45 million and $50 million in 2025[13, 43] - The company expects operating expense growth to be less than 5% in 2025[13, 43] Key Performance Indicators - Total annual contract value (ACV) increased from $154.2 million in 2023 to $190.8 million in 2024[39] - The number of customers with ACV ≥$5M doubled from 4 in 2023 to 8 in 2024[39]

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 27, 2023 Registration No. 333-273465 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Adlai Nortye Ltd. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Adlai Nortye Ltd. c/o PO Box 309, Ugland H ...

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 12, 2023 Registration No. 333-273465 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Adlai Nortye Ltd. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Adlai Nortye Ltd. c/o PO Box 309, Ugland H ...

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 27, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Adlai Nortye Ltd. (Exact name of Registrant as specified in its charter) (Primary Standard Industrial Classification Code Number) Cayman Islands 2834 Not Applicable (I.R.S. Employer Identification Number) Adlai Nortye Ltd. c/o PO Box 309, Ugland House Grand Cayman, ...

As filed with the Securities and Exchange Commission on June 30, 2023. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Allarity Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Delaware 2834 87-2147982 (I.R.S. Employer Identification No.) Classification Code Number) 24 School Street, 2n ...